D. Kelly

G. Payne, D. Kelly, R. Ghodssi, 2013, 2013 Transducers & Eurosensors XXVII: The 17th International Conference on Solid-State Sensors, Actuators and Microsystems (TRANSDUCERS & EUROSENSORS XXVII).

Fluoxetine augmentation of haloperidol in chronic schizophrenia

R. Conley, D. Kelly, J. Shim, 2003, Schizophrenia Research.

Neurologic and Psychiatric Manifestations of Celiac Disease and Gluten Sensitivity

D. Kelly, W. Eaton, N. Cascella, 2012, Psychiatric Quarterly.

An integrated electrochemical microsystem for real-time treatment monitoring of clozapine in microliter volume samples from schizophrenia patients

Rajendra P. Shukla, D. Kelly, H. Ben‐Yoav, 2020 .

Current status of clozapine in the United States

D. Kelly, H. Wehring, Gopal R. Vyas, 2012, Shanghai archives of psychiatry.

Relationship of Interferon-γ to Cognitive Function in Midlife Women with Schizophrenia

D. Kelly, H. Wehring, L. Rubin, 2018, Psychiatric Quarterly.

The 2009 schizophrenia patient outcomes research team (PORT) psychopharmacological treatment recommendations

D. Kelly, D. Boggs, R. Buchanan, 2011 .

Cervical cancer screening and acute care visits among Medicaid enrollees with mental and substance use disorders.

D. Kelly, S. Feldman, M. Abrams, 2012, Psychiatric services.

A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.

R. Conley, D. Kelly, D. Boggs, 2009, The Journal of clinical psychiatry.

Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia

D. Kelly, D. Boggs, R. McMahon, 2013, Psychiatry Research.

A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia

R. Conley, D. Kelly, 2006, Psychoneuroendocrinology.

Cardiovascular Disease Mortality in Chronic Schizophrenia Patients Treated with Clozapine

R. Conley, D. Kelly, H. Wehring, 2013 .

Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients.

R. Conley, D. Kelly, 2007, Psychopharmacology bulletin.

Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine.

J J Bartko, R. Conley, D. Kelly, 1999, The American journal of psychiatry.

Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death.

R. Conley, D. Kelly, S. Feldman, 2004, Journal of psychiatric research.

A dose-outcome analysis of risperidone.

R. Conley, D. Kelly, R. Love, 1999, The Journal of clinical psychiatry.

Novel Factor-Based Symptom Scores in Treatment Resistant Schizophrenia: Implications for Clinical Trials

R. Conley, D. Kelly, R. Love, 2002, Neuropsychopharmacology.

Evaluation of the Safety of Clozapine Use in Patients With Benign Neutropenia.

D. Kelly, E. Davis, B. DiPaula, 2016, The Journal of clinical psychiatry.

Tryptophan Challenge in Healthy Controls and People with Schizophrenia: Acute Effects on Plasma Levels of Kynurenine, Kynurenic Acid and 5-Hydroxyindoleacetic Acid

D. Kelly, R. Schwarcz, R. Buchanan, 2022, Pharmaceuticals.

Role of chronic stress and depression in periodontal diseases

Postolache, D. Kelly, Kimberly R. Warren, 2014, BDJ.

Diagnostic criteria for cannabis withdrawal syndrome.

D. Kelly, D. Boggs, S. Heishman, 2012, Drug and alcohol dependence.

Elevated zonulin, a measure of tight-junction permeability, may be implicated in schizophrenia

D. Kelly, W. Eaton, N. Cascella, 2019, Schizophrenia Research.

Immunologic profiling in schizophrenia and rheumatoid arthritis

Kimberly B. Roth, D. Kelly, W. Eaton, 2022, Psychiatry Research.

25-Hydroxyvitamin D and metabolic-related laboratory values in women with schizophrenia and hyperprolactinemia.

Megan M. Powell, D. Kelly, H. Wehring, 2022, Journal of psychiatric research.

Cannabis withdrawal in chronic cannabis users with schizophrenia.

D. Kelly, D. Boggs, D. Gorelick, 2013, Journal of psychiatric research.

Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

R. Conley, D. Kelly, J. Shim, 2007, The American journal of psychiatry.

Pharmacokinetics and Safety Assessment of l‐Tetrahydropalmatine in Cocaine Users: A Randomized, Double‐Blind, Placebo‐Controlled Study

D. Kelly, H. Wehring, S. Feldman, 2017, Journal of clinical pharmacology.

Simultaneous determination of L-tetrahydropalmatine and cocaine in human plasma by simple UPLC-FLD method: application in clinical studies.

D. Kelly, K. Bauer, Ahmed M. Ibrahim, 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.

D. Kelly, M. Huestis, D. Gorelick, 2009, Clinical chemistry.

Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia

R. Conley, D. Kelly, S. Feldman, 2006, Psychiatric Quarterly.

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Julie Kreyenbuhl, Deanna L Kelly, D. Kelly, 2010, Schizophrenia bulletin.

Treatments for the Prevention and Management of Suicide

D. Kelly, H. Wehring, R. Buchanan, 2020, Annals of Internal Medicine.

Molecular processes in an electrochemical clozapine sensor.

Eunkyoung Kim, G. Payne, D. Kelly, 2017, Biointerphases.

The risk of suicide after clozapine discontinuation: Cause for concern.

D. Kelly, Gopal R. Vyas, K. Patchan, 2015, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder

D. Kelly, H. Wehring, Kimberly R. Warren, 2013, Schizophrenia Research.

First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

R. Conley, D. Kelly, W. Carpenter, 2005, Drugs.

The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study.

R. Conley, D. Kelly, C. Tamminga, 2003, Journal of clinical psychopharmacology.

Plasma concentrations of high‐dose olanzapine in a double‐blind crossover study

R. Conley, D. Kelly, Yang Yu, 2006, Human psychopharmacology.

Intelligent Multi-Electrode Array for Real-Time Treatment Monitoring of Antipsychotic Clozapine

Rajendra P. Shukla, D. Kelly, H. Ben‐Yoav, 2020 .

Comparison of clozapine use in Maryland and in Victoria, Australia.

R. Conley, D. Kelly, R. Love, 2005, Psychiatric services.

Reliable clinical serum analysis with reusable electrochemical sensor: Toward point-of-care measurement of the antipsychotic medication clozapine.

George E. Banis, Eunkyoung Kim, G. Payne, 2017, Biosensors & bioelectronics.

Clozapine utilization and outcomes by race in a public mental health system: 1994-2000.

R. Conley, D. Kelly, R. Love, 2006, The Journal of clinical psychiatry.

Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report.

D. Kelly, J. Shim, Y. You, 2008, Journal of clinical psychopharmacology.

The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia.

R. Conley, D. Kelly, J. Shim, 2005, Journal of clinical psychopharmacology.

The effect of Vitamin C for point-of-care blood analysis applications using an electrochemical biosensor

Eunkyoung Kim, G. Payne, D. Kelly, 2013, 2013 IEEE SENSORS.

Differential olanzapine plasma concentrations by sex in a fixed-dose study

R. Conley, D. Kelly, C. Tamminga, 1999, Schizophrenia Research.

Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia

R. Conley, D. Kelly, C. Tamminga, 2003, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects.

R. Conley, D. Kelly, 2005, The Israel journal of psychiatry and related sciences.

Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels

D. Kelly, H. Wehring, S. Feldman, 2018, Psychiatric Quarterly.

Quetiapine at high doses for the treatment of refractory schizophrenia

R. Conley, D. Kelly, D. Boggs, 2008, Schizophrenia Research.

Connecting Biology to Electronics: Molecular Communication via Redox Modality

Gregory F. Payne, Yi Liu, Jinyang Li, 2017, Advanced healthcare materials.

Fusing Sensor Paradigms to Acquire Chemical Information: An Integrative Role for Smart Biopolymeric Hydrogels

Yi Liu, Kun Yan, Xiaowen Shi, 2016, Advanced healthcare materials.

Redox Is a Global Biodevice Information Processing Modality

Si Wu, Shuo Chen, Gregory F. Payne, 2019, Proceedings of the IEEE.

Clozapine in Reducing Aggression and Violence in Forensic Populations

D. Kelly, S. Feldman, R. Love, 2018, Psychiatric Quarterly.

Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles

M. Daly, D. Rujescu, K. Shianna, 2014, Nature Communications.

Electrochemical study of the catechol-modified chitosan system for clozapine treatment monitoring.

Hadar Ben-Yoav, Gregory F Payne, Reza Ghodssi, 2014, Langmuir : the ACS journal of surfaces and colloids.

Redox cycling-based amplifying electrochemical sensor for in situ clozapine antipsychotic treatment monitoring

Gregory F. Payne, Hadar Ben-Yoav, Reza Ghodssi, 2014 .

Blood–brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders

D. Kelly, N. Cascella, A. Fasano, 2016, Molecular Autism.

Biperiden for excessive sweating from clozapine.

R. Conley, D. Kelly, C. Richardson, 2001, American Journal of Psychiatry.

L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia

D. Kelly, H. Wehring, S. Hoag, 2020, Schizophrenia Bulletin Open.

Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.

D. Kelly, J. Waltz, J. Gold, 2015, Schizophrenia bulletin.

Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis.

R. Conley, D. Kelly, T. Lambert, 2004, Journal of clinical psychopharmacology.

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

F. Dickerson, D. Kelly, H. Wehring, 2013, BMC Psychiatry.

Treatment considerations in women with schizophrenia.

Deanna L Kelly, D. Kelly, 2006, Journal of women's health.

A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies

D. Kelly, Kimberly R. Warren, S. Feldman, 2012, Schizophrenia Research.

Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study

Megan M. Powell, D. Kelly, H. Wehring, 2019, Journal of psychiatry & neuroscience : JPN.

Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia

S. A. Wijtenburg, D. Kelly, L. Rowland, 2017, Front. Psychiatry.

Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers.

D. Kelly, D. Boggs, S. Heishman, 2010, Drug and alcohol dependence.

Clinical characteristics of heavy and non-heavy smokers with schizophrenia

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Schizophrenia Research.

Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia.

D. Kelly, H. Wehring, S. Feldman, 2012, Schizophrenia bulletin.

Circumstances of suicide among individuals with schizophrenia

R. Conley, D. Kelly, J. Kreyenbuhl, 2002, Schizophrenia Research.

Management of treatment resistance in schizophrenia

R. Conley, D. Kelly, 2001, Biological Psychiatry.

Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers.

D. Kelly, M. Huestis, D. Gorelick, 2013, Journal of analytical toxicology.

Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.

D. Kelly, M. Huestis, D. Gorelick, 2012, Drug and alcohol dependence.

Increased circulating regulatory T cells in medicated people with schizophrenia

D. Kelly, S. Feldman, R. Buchanan, 2018, Psychiatry Research.

Undiagnosed Lyme disease in adults with schizophrenia

D. Kelly, H. Wehring, S. Feldman, 2015, Schizophrenia Research.

Tobacco craving in smokers with and without schizophrenia

D. Kelly, H. Wehring, S. Feldman, 2011, Schizophrenia Research.

Consensus statement on the use of clozapine during the COVID-19 pandemic.

W. Honer, A. Wheeler, D. Kelly, 2020, Journal of psychiatry & neuroscience : JPN.

Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine.

R. Conley, D. Kelly, 2005, The Journal of clinical psychiatry.

Measurement of antipsychotic‐induced side effects: Support for the validity of a self‐report (LUNSERS) versus structured interview (UKU) approach to measurement

R. Conley, D. Kelly, T. Lambert, 2003, Human psychopharmacology.

Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response

R. Conley, D. Kelly, C. Tamminga, 1999, Biological Psychiatry.

Kynurenine and Tryptophan Levels in Patients With Schizophrenia and Elevated Antigliadin Immunoglobulin G Antibodies

Andrew J. Hoisington, D. Rujescu, I. Giegling, 2016, Psychosomatic medicine.

Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness

D. Kelly, H. Wehring, R. Love, 2022, Schizophrenia Research.

Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management

D. Kelly, R. Love, 2019, The mental health clinician.

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.

D. Kelly, E. Seifritz, Abraham Weizman, 2021, Pharmacopsychiatry.

Clozapine Treatment in Patients with Prior Substance Abuse

R. Conley, D. Kelly, E. Gale, 2003, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

Illicit drug use in heavy smokers with and without schizophrenia

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Schizophrenia Research.

First-Episode Schizophrenia

R. Conley, D. Kelly, W. Carpenter, 2012, Drugs.

Drugs 2005; 65 (8): 1113-1138

R. Conley, D. Kelly, W. Carpenter, 2005 .

Comparison of Clozapine Response for Inpatients in the Research Setting Versus Routine Clinical Practice

R. Conley, D. Kelly, D. Boggs, 2008, Psychiatric Quarterly.

Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial

D. Kelly, J. Shim, Saejeong Lee, 2012, Neuropsychopharmacology.

Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil

D. Kelly, Yangchun Du, A. Claxton, 2021, Psychiatry Research.

Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial

Megan M. Powell, F. Dickerson, D. Kelly, 2018, Journal of clinical psychopharmacology.

Sexuality and schizophrenia: a review.

R. Conley, D. Kelly, 2004, Schizophrenia bulletin.

Reaching for wellness in schizophrenia.

R. Conley, D. Kelly, D. Boggs, 2007, The Psychiatric clinics of North America.

Why Not Clozapine

A. Malhotra, D. Kelly, R. Buchanan, 2007 .

Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.

R. Conley, D. Kelly, D. Boggs, 2010, Comprehensive psychiatry.

Pilot study examining the relationship of childhood trauma, perceived stress, and medication use to serum kynurenic acid and kynurenine levels in schizophrenia

D. Kelly, L. Rowland, Matthew Glassman, 2017, Schizophrenia Research.

Urine testing for antipsychotics: a pilot trial for a method to determine detection levels

D. Kelly, H. Wehring, S. Feldman, 2015, Human psychopharmacology.

Risperidone, Quetiapine, and Fluphenazine in the Treatment of Patients With Therapy-Refractory Schizophrenia

R. Conley, D. Kelly, S. Feldman, 2005, Clinical neuropharmacology.

Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.

D. Kelly, M. Huestis, D. Gorelick, 2011, Clinical chemistry.

Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia

D. Kelly, H. Wehring, S. Feldman, 2017, Journal of dual diagnosis.

Current status of antipsychotic treatment.

R. Conley, D. Kelly, 2002, Current drug targets. CNS and neurological disorders.

Gut permeability and mimicry of the Glutamate Ionotropic Receptor NMDA type Subunit Associated with protein 1 (GRINA) as potential mechanisms related to a subgroup of people with schizophrenia with elevated antigliadin antibodies (AGA IgG)

D. Kelly, S. Feldman, W. Eaton, 2019, Schizophrenia Research.

Gluten sensitivity and relationship to psychiatric symptoms in people with schizophrenia

D. Kelly, S. Feldman, W. Eaton, 2014, Schizophrenia Research.

Elevated gliadin antibody levels in individuals with schizophrenia

D. Rujescu, I. Giegling, A. Hartmann, 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

Can the current schizophrenia construct endure?

D. Kelly, R. Buchanan, 2022, Schizophrenia Research.

Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms

D. Kelly, H. Wehring, R. Buchanan, 2011, Schizophrenia Research.

Increased prevalence of transglutaminase 6 antibodies in sera from schizophrenia patients.

D. Kelly, W. Eaton, N. Cascella, 2013, Schizophrenia bulletin.

Around-the-clock oral THC effects on sleep in male chronic daily cannabis smokers.

D. Kelly, M. Huestis, D. Gorelick, 2013, The American journal on addictions.

The Effects of a Gluten-Free Diet on Immune Markers and Kynurenic Acid Pathway Metabolites in Patients With Schizophrenia Positive for Antigliadin Antibodies Immunoglobulin G.

Megan M. Powell, D. Kelly, H. Wehring, 2020, Journal of clinical psychopharmacology.

Anti gliadin antibodies (AGA IgG) related to peripheral inflammation in schizophrenia

D. Kelly, W. Eaton, W. Carpenter, 2018, Brain, Behavior, and Immunity.

Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials

D. Kelly, G. Ungvari, Shi-bin Wang, 2017, European Neuropsychopharmacology.

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms

D. Kelly, H. Wehring, S. Feldman, 2015, Journal of clinical psychopharmacology.

A review of anti-inflammatory agents for symptoms of schizophrenia

D. Kelly, H. Wehring, R. Buchanan, 2013, Journal of psychopharmacology.

Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial

R. Conley, D. Kelly, D. Boggs, 2012, Schizophrenia Research.

Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia: A Randomized, Double-Blind, Pilot Study

R. Conley, D. Kelly, H. Wehring, 2011, Journal of clinical psychopharmacology.

The Binding Effect of Proteins on Medications and Its Impact on Electrochemical Sensing: Antipsychotic Clozapine as a Case Study

George E. Banis, Eunkyoung Kim, G. Payne, 2017, Pharmaceuticals.

Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie.

D. Goff, D. Kelly, J. Newcomer, 2020, The Journal of clinical psychiatry.

Redox Probing for Chemical Information of Oxidative Stress

Gregory F Payne, William E Bentley, Reza Ghodssi, 2016, Analytical chemistry.

Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia

D. Kelly, H. Wehring, R. Love, 2019, Psychiatric Quarterly.

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.

R. Conley, D. Kelly, R. Love, 2008, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

Signal processing approach to probe chemical space for discriminating redox signatures.

Shuo Chen, Eunkyoung Kim, Gregory F Payne, 2018, Biosensors & bioelectronics.

Peripheral oxytocin and vasopressin are associated with clinical symptom severity and cognitive functioning in midlife women with chronic schizophrenia

C. Carter, D. Kelly, H. Wehring, 2017, Schizophrenia Research.

Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.

D. Kelly, D. Boggs, John M. Davis, 2008, Schizophrenia bulletin.

Complexity of oxytocin׳s effects in a chronic cocaine dependent population

B. King-Casas, D. Kelly, E. Stein, 2014, European Neuropsychopharmacology.

Prevalence of Childhood Physical and Sexual Abuse in Veterans With Psychiatric Diagnoses

B. Bradley, D. Kelly, Erica Duncan, 2013, The Journal of nervous and mental disease.

Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia

R. Conley, D. Kelly, D. Boggs, 2008, Schizophrenia Research.

Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.

D. Kelly, M. Huestis, D. Gorelick, 2010, Clinical chemistry.

Predictors of the Perception of Smoking Health Risks in Smokers With or Without Schizophrenia

William J. Kowalczyk, D. Kelly, H. Wehring, 2017, Journal of dual diagnosis.

Oxytocin and sexual function in males and females with schizophrenia

D. Kelly, H. Wehring, S. Feldman, 2018, Schizophrenia Research.

Association of acute psychosocial stress with oxidative stress: Evidence from serum analysis

W. Bentley, G. Payne, D. Kelly, 2021, Redox biology.

A Randomized Clinical Trial of Oxytocin or Galantamine in Schizophrenia: Assessing the Impact on Behavioral, Lexical, and Self-Report Indicators of Social Affiliation

D. Kelly, J. Gold, R. Buchanan, 2020, Schizophrenia bulletin open.

D. Kelly, H. Wehring, S. Feldman, 2009, Schizophrenia Research.

Consensus statement on the use of clozapine during the COVID-19 pandemic

W. Honer, A. Wheeler, D. Kelly, 2020, Journal of psychiatry & neuroscience : JPN.

Cortisol response to buspirone in extended abstinent alcoholics.

R. Conley, D. Kelly, J. Shim, 2004, Alcohol and alcoholism.

A Longitudinal Examination of Real-World Sedentary Behavior in Adults with Schizophrenia-Spectrum Disorders in a Clinical Trial of Combined Oxytocin and Cognitive Behavioral Social Skills Training

Philip D. Harvey, E. Granholm, Jason Holden, 2022, Behavioral Science.

Schizophrenia clinical symptom differences in women vs. men with and without a history of childhood physical abuse

D. Kelly, S. Feldman, L. Rowland, 2016, Child and Adolescent Psychiatry and Mental Health.

Peripheral Cortisol and Inflammatory Response to a Psychosocial Stressor in People with Schizophrenia

D. Kelly, H. Wehring, L. Rowland, 2018, Journal of neuropsychiatry.

The effects of combined oxytocin and cognitive behavioral social skills training on social cognition in schizophrenia

E. Granholm, Jason Holden, D. Kelly, 2018, Psychological Medicine.

Mediated Electrochemical Probing: A Systems-Level Tool for Redox Biology.

W. Bentley, Eunkyoung Kim, G. Payne, 2021, ACS chemical biology.

The Role of Microsystems Integration Towards Point-of-Care Clozapine Treatment Monitoring in Schizophrenia

Gregory F. Payne, Eunkyoung Kim, Reza Ghodssi, 2018, IEEE Sensors Letters.

The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report

D. Kelly, H. Wehring, R. Buchanan, 2019, Journal of psychiatry and brain science.

A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia

D. Kelly, J. Gold, R. Buchanan, 2017, Journal of clinical psychopharmacology.

Evidence-Based Medicine

D. Kelly, L. Dixon, Gina Perez, 2010 .

Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: Results from a randomized double blind placebo controlled pilot study

D. Kelly, H. Wehring, R. Buchanan, 2013, Schizophrenia Research.

Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse

R. Conley, D. Kelly, E. Gale, 1998, Schizophrenia Research.

The Potential Role of Long-Acting Injectable Antipsychotics in People With Schizophrenia and Comorbid Substance Use

D. Kelly, H. Wehring, M. Koola, 2012, Journal of dual diagnosis.

The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study

A. Cohen, D. Kelly, R. Buchanan, 2017, Schizophrenia Research.

Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia

D. Kelly, H. Wehring, R. Buchanan, 2016, Schizophrenia Research.

Exercise Program Adherence Using a 5-Kilometer (5K) Event as an Achievable Goal in People With Schizophrenia

D. Kelly, Kimberly R. Warren, S. Feldman, 2011, Biological research for nursing.

Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia

E. Granholm, Jason Holden, D. Kelly, 2021, Journal of clinical psychopharmacology.

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

D. Kelly, H. Wehring, M. Koola, 2011, Journal of central nervous system disease.

Adjunctive Risperidone for Partially Responsive People with Schizophrenia Treated with Clozapine

R. Conley, D. Kelly, S. Feldman, 2010, Neuropsychopharmacology.

The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders

D. Kelly, S. Feldman, J. Shim, 2011, Osteoporosis International.

Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders.

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Journal of psychiatric research.

Levels of prolactin and testosterone and associated sexual dysfunction and breast abnormalities in men with schizophrenia treated with antipsychotic medications.

D. Kelly, Christopher Kitchen, P. Bezwada, 2021, Journal of psychiatric research.

Multimodal Approach for Assessing Neuromotor Coordination in Schizophrenia Using Convolutional Neural Networks

Yashish M. Siriwardena, C. Espy-Wilson, D. Kelly, 2021, ICMI.

Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study

D. Kelly, R. Buchanan, Alison S Buchholz, 2011, Schizophrenia Research.

Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.

D. Kelly, Kimberly R. Warren, S. Feldman, 2011, Clinical schizophrenia & related psychoses.

Effects of intranasal oxytocin on satiety signaling in people with schizophrenia

D. Kelly, H. Wehring, Kimberly R. Warren, 2018, Physiology & Behavior.

Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study.

R. Conley, D. Kelly, H. Wehring, 2010, The Journal of clinical psychiatry.

Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia.

D. Kelly, H. Wehring, J. Gold, 2020, Journal of clinical psychopharmacology.

Fluoxetine augmentation of haloperidol in chronic schizophrenia.

R. Conley, D. Kelly, J. Shim, 2003 .

Bone Mineral Density and Osteoporosis Risk in Older Patients With Schizophrenia

D. Kelly, J. Shim, B. Kong, 2011, Journal of clinical psychopharmacology.

Clinical Pharmacology and Medication-Associated Side Effects: A Review of Second-Generation Antipsychotics for Schizophrenia

R. Conley, D. Kelly, 2007 .

Racial Differences in S100b Levels in Persons with Schizophrenia

D. Kelly, J. Brar, D. Čiháková, 2019, Psychiatric Quarterly.

Can language use in social media help in the treatment of severe mental illness?

P. Resnik, D. Kelly, Glen A. Coppersmith, 2021, Current research in psychiatry.

Tryptophan challenge in individuals with schizophrenia and healthy controls: acute effects on circulating kynurenine and kynurenic acid, cognition and cerebral blood flow

S. A. Wijtenburg, D. Kelly, R. Schwarcz, 2023, Neuropsychopharmacology.

Reduced arterial compliance in patients with psychiatric diagnoses

D. Kelly, Erica Duncan, C. Qualls, 2012, Schizophrenia Research.

Evaluating the Use of Online Self-Report Questionnaires as Clinically Valid Mental Health Monitoring Tools in the Clinical Whitespace

P. Resnik, D. Kelly, Glen A. Coppersmith, 2023, Psychiatric Quarterly.

Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study.

R. Conley, D. Kelly, J. Shim, 2006, The Journal of clinical psychiatry.

Prebiotic Treatment Increases Serum Butyrate in People With Schizophrenia

D. Kelly, R. Buchanan, M. Kane, 2021, Journal of clinical psychopharmacology.

Multidimensional Mapping Method Using an Arrayed Sensing System for Cross-Reactivity Screening

Gregory F. Payne, Hadar Ben-Yoav, Reza Ghodssi, 2015, PloS one.

Redox-Enabled Bio-Electronics for Information Acquisition and Transmission

W. Bentley, Eunkyoung Kim, G. Payne, 2023, IEEE Transactions on Molecular, Biological and Multi-Scale Communications.

Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.

D. Kelly, R. Love, 2001, Psychopharmacology bulletin.

Nutrition in the Treatment of Schizophrenia: Rationale and Review of Recent Evidence

D. Kelly, S. Kulaga, 2023, Current Behavioral Neuroscience Reports.

Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.

R. Conley, D. Kelly, J. Shim, 2007, Journal of clinical psychopharmacology.

College of Psychiatric and Neurologic Pharmacists 2012 Poster Abstracts

Hepburn, D. Kelly, H. Wehring, 2012 .

Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia

H. Stefánsson, D. Rujescu, A. Jonasdottir, 2016, Molecular Psychiatry.

The Role of Board Certified Psychiatric Pharmacists in Expanding Access to Care and Improving Patient Outcomes.

Howard Y. Liu, D. Kelly, A. Young, 2021, Psychiatric Services.

Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia

M. Daly, H. Stefánsson, D. Rujescu, 2016, Molecular Psychiatry.

Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.

R. Conley, D. Kelly, R. Love, 2003, The Journal of clinical psychiatry.

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia

D. Kelly, E. Vieta, L. Culpepper, 2022, Neuropsychiatric disease and treatment.

Perception of Depot Antipsychotics by Mental Health Professionals

R. Conley, D. Kelly, T. Lambert, 2003, Journal of psychiatric practice.

ADJUNCTIVE MINOCYCLINE IN CLOZAPINE TREATED SCHIZOPHRENIA PATIENTS

D. Kelly, H. Wehring, S. Feldman, 2014, Schizophrenia Research.

TOBACCO MOSAIC VIRUS BIOTEMPLATED ELECTROCHEMICAL BIOSENSOR

D. Kelly, R. Ghodssi, E. Pomerantseva, 2012 .

Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia

D. Kelly, D. Boggs, R. McMahon, 2013, Psychiatry Research.

Antagonist-Elicited Cannabis Withdrawal in Humans

D. Kelly, M. Huestis, D. Gorelick, 2011, Journal of clinical psychopharmacology.

Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population.

D. Kelly, W. Eaton, N. Cascella, 2011, Schizophrenia bulletin.

A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies

D. Kelly, Kimberly R. Warren, S. Feldman, 2012, Schizophrenia Research.

Inverted Vocal Tract Variables and Facial Action Units to Quantify Neuromotor Coordination in Schizophrenia

Carol Espy-Wilson, Deanna L. Kelly, Yashish Maduwantha H.P.E.R.S, 2021, 2102.07054.

Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone.

R. Conley, D. Kelly, M. Nelson, 2003, Clinical neuropharmacology.

Prevalence of Childhood Physical and Sexual Abuse in Veterans With Psychiatric Diagnoses

B. Bradley, D. Kelly, Erica Duncan, 2013, The Journal of nervous and mental disease.

The relationship of peripheral inflammation with antibodies to gliadin (AGA IgG) in persons with schizophrenia

D. Kelly, W. Eaton, D. Čiháková, 2023, Schizophrenia Research.

Signal processing approach to probe chemical space for discriminating redox signatures.

W. Bentley, Eunkyoung Kim, G. Payne, 2018, Biosensors & bioelectronics.

The Analgesic Acetaminophen and the Antipsychotic Clozapine Can Each Redox-Cycle with Melanin.

Jinyang Li, Lucia Panzella, Alessandra Napolitano, 2017, ACS chemical neuroscience.

Electrochemical study of the catechol-modified chitosan system for clozapine treatment monitoring.

Eunkyoung Kim, G. Payne, D. Kelly, 2014, Langmuir : the ACS journal of surfaces and colloids.

Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial

D. Kelly, H. Wehring, R. Love, 2023, Schizophrenia Research.

Illicit drug use in heavy smokers with and without schizophrenia

D. Kelly, H. Wehring, Kristen M. Mackowick, 2012, Schizophrenia Research.